[1] Zhou J, Zhou F, Wang W, et al. Epidemiological features of NAFLD from 1999 to 2018 in China. Hepatology, 2020,71(5):1851-1864.
[2] Sanyal A, Charles ED, Neuschwander-Tetri BA, et al. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial. Lancet, 2019,392(10165):2705-2717.
[3] Harrison SA, Ruane PJ, Freilich BL, et al. Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial. Nat Med, 2021,27(7):1262-1271.
[4] Fisher FM, Maratos-Flier E. Understanding the physiology of FGF21. Annu Rev Physiol, 2016,78:223-241.
[5] Zarei M, Pizarro-Delgado J, Barroso E, et al. Targeting FGF21 for the treatment of nonalcoholic steatohepatitis. Trends Pharmacol Sci, 2020,41(3):199-208.
[6] Lin Z, Tian H, Lam KS, et al. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice. Cell Metab, 2013,17(5):779-789.
[7] Henriksson E, Andersen B. FGF19 and FGF21 for the treatment of NASH-Two sides of the same coin? Differential and overlapping effects of FGF19 and FGF21 from mice to human. Front Endocrinol (Lausanne), 2020,11:601349.
[8] Barb D, Bril F, Kalavalapalli S, et al. Plasma fibroblast growth factor 21 is associated with severity of nonalcoholic steatohepatitis in patients with obesity and type 2 diabetes. J Clin Endocrinol Metab, 2019,104(8):3327-3336.
[9] Tucker B, Li H, Long X, et al. Fibroblast growth factor 21 in non-alcoholic fatty liver disease. Metabolism, 2019,101:153994.
[10] Liu W, Sun C, Yan Y, et al. Hepatic P38 activation modulates systemic metabolism through Fgf21-mediated interorgan communication. Diabetes, 2021.
[11] Sanchez-Garrido MA, Habegger KM, Clemmensen C, et al. Fibroblast activation protein (FAP) as a novel metabolic target. Mol Metab, 2016,5(10):1015-1024.
[12] Geng L, Lam KSL, Xu A. The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic. Nat Rev Endocrinol, 2020,16(11):654-667.
[13] Charles ED, Neuschwander-Tetri BA, Pablo Frias J, et al. Pegbelfermin (BMS-986036), PEGylated FGF21, in patients with obesity and type 2 diabetes: results from a randomized phase 2 study. Obesity (Silver Spring), 2019,27(1):41-49.
[14] Kaufman A, Abuqayyas L, Denney WS, et al. AKR-001, an Fc-FGF21 analog, showed sustained pharmacodynamic effects on insulin sensitivity and lipid metabolism in type 2 diabetes patients. Cell Rep Med, 2020,1(4):100057.
[15] Zhang Y, Lei T, Huang JF, et al. The link between fibroblast growth factor 21 and sterol regulatory element binding protein 1c during lipogenesis in hepatocytes. Mol Cell Endocrinol, 2011,342(1-2):41-47.
[16] Fisher FM, Chui PC, Nasser IA, et al. Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. Gastroenterology, 2014,147(5):1073-1083 e1076.
[17] Zarei M, Barroso E, Palomer X, et al. Hepatic regulation of VLDL receptor by PPARbeta/delta and FGF21 modulates non-alcoholic fatty liver disease. Mol Metab, 2018,8:117-131.
[18] Zhu S, Wu Y, Ye X, et al. FGF21 ameliorates nonalcoholic fatty liver disease by inducing autophagy. Mol Cell Biochem, 2016,420(1-2):107-119.
[19] Fisher FM, Kleiner S, Douris N, et al. FGF21 regulates PGC-1alpha and browning of white adipose tissues in adaptive thermogenesis. Genes Dev, 2012,26(3):271-281.
[20] Cho YM, Kim DH, Lee KH, et al. The IRE1alpha-XBP1s pathway promotes insulin-stimulated glucose uptake in adipocytes by increasing PPARgamma activity. Exp Mol Med, 2018,50(8):1-15.
[21] 王静, 白秀平. 成纤维细胞生长因子21与糖脂代谢的研究进展. 中国医药, 2021,16(03):470-472.
[22] Lin X, Liu YB, Hu H. Metabolic role of fibroblast growth factor 21 in liver, adipose and nervous system tissues. Biomed Rep, 2017,6(5):495-502.
[23] Singhal G, Fisher FM, Chee MJ, et al. Fibroblast growth factor 21 (FGF21) protects against high fat diet induced inflammation and islet hyperplasia in pancreas. PLoS One, 2016,11(2):e0148252.
[24] Yu Y, He J, Li S, et al. Fibroblast growth factor 21 (FGF21) inhibits macrophage-mediated inflammation by activating Nrf2 and suppressing the NF-kappaB signaling pathway. Int Immunopharmacol, 2016,38:144-152.
[25] Bao L, Yin J, Gao W, et al. A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway. Br J Pharmacol, 2018,175(16):3379-3393.
[26] Yu Y, Bai F, Liu Y, et al. Fibroblast growth factor (FGF21) protects mouse liver against D-galactose-induced oxidative stress and apoptosis via activating Nrf2 and PI3K/Akt pathways. Mol Cell Biochem, 2015,403(1-2):287-299.
[27] Chau MD, Gao J, Yang Q, et al. Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway. Proc Natl Acad Sci U S A, 2010,107(28):12553-12558.
[28] Jiang S, Yan C, Fang QC, et al. Fibroblast growth factor 21 is regulated by the IRE1alpha-XBP1 branch of the unfolded protein response and counteracts endoplasmic reticulum stress-induced hepatic steatosis. J Biol Chem, 2014,289(43):29751-29765.
[29] Xu P, Zhang Y, Liu Y, et al. Fibroblast growth factor 21 attenuates hepatic fibrogenesis through TGF-beta/smad2/3 and NF-kappaB signaling pathways. Toxicol Appl Pharmacol, 2016,290:43-53.
[30] Meng F, Khoso MH, Kang K, et al. FGF21 ameliorates hepatic fibrosis by multiple mechanisms. Mol Biol Rep, 2021,48(11):7153-7163.
[31] Singhal G, Kumar G, Chan S, et al. Deficiency of fibroblast growth factor 21 (FGF21) promotes hepatocellular carcinoma (HCC) in mice on a long term obesogenic diet. Mol Metab, 2018,13:56-66.
[32] Zheng Q, Martin RC, Shi X, et al. Lack of FGF21 promotes NASH-HCC transition via hepatocyte-TLR4-IL-17A signaling. Theranostics, 2020,10(22):9923-9936.
[33] Wei W, Dutchak PA, Wang X, et al. Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor gamma. Proc Natl Acad Sci U S A, 2012,109(8):3143-3148. |
